MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$71.47
+3.18%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-13.6%
Return on equity
-13.2%
Return on assets
-16.9%
Return on invested capital
0.00x
Asset turnover
-$3.3B
Cash from operations
$20
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026